Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J. Yuan Y, et al. Among authors: tang a. Oncologist. 2021 Mar;26(3):e382-e393. doi: 10.1002/onco.13574. Epub 2020 Nov 8. Oncologist. 2021. PMID: 33098195 Free PMC article. Clinical Trial.
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, Robinson K, Tang A, Martinez N, Portnow J, Wen W, Yim JH, Brauer HA, Ren Y, Luu T, Mortimer J, Yuan Y. Lee JS, et al. Among authors: tang a. Breast Cancer Res. 2019 Nov 8;21(1):119. doi: 10.1186/s13058-019-1202-4. Breast Cancer Res. 2019. PMID: 31703728 Free PMC article. Clinical Trial.
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK, Robinson K, Padam S, Martinez N, Tang A, Schmolze D, Waisman J, Sedrak M, Lee PP, Mortimer J. Yuan Y, et al. Among authors: tang a. Oncologist. 2021 Feb;26(2):99-e217. doi: 10.1002/onco.13583. Epub 2020 Nov 24. Oncologist. 2021. PMID: 33141975 Free PMC article. Clinical Trial.
Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.
Yuan Y, Lee JS, Yost SE, Stiller T, Blanchard MS, Padam S, Katheria V, Kim H, Sun C, Tang A, Martinez N, Patel ND, Sedrak MS, Waisman J, Li D, Sanani S, Presant CA, Mortimer J. Yuan Y, et al. Among authors: tang a. J Geriatr Oncol. 2021 Jun;12(5):752-758. doi: 10.1016/j.jgo.2021.02.020. Epub 2021 Mar 2. J Geriatr Oncol. 2021. PMID: 33663941 Free PMC article. Clinical Trial.
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N, Schmolze D, Presant C, Ebrahimi B, Yeon C, Sedrak M, Patel N, Portnow J, Lee P, Mortimer J. Yuan Y, et al. Among authors: tang a. Eur J Cancer. 2021 Sep;154:11-20. doi: 10.1016/j.ejca.2021.05.035. Epub 2021 Jul 1. Eur J Cancer. 2021. PMID: 34217908 Free PMC article. Clinical Trial.
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
Ge X, Yost SE, Lee JS, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Chung S, Yeon C, Stewart D, Li D, Rajurkar S, Somlo G, Mortimer J, Waisman J, Yuan Y. Ge X, et al. Among authors: tang a. Cancers (Basel). 2022 Sep 1;14(17):4279. doi: 10.3390/cancers14174279. Cancers (Basel). 2022. PMID: 36077811 Free PMC article.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Among authors: tang a. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Among authors: tang a. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: tang a. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
Yuan Y, Egelston C, Colunga Flores O, Chaurasiya S, Lin D, Chang H, Chong LMO, Seiz A, Shah M, Meisen WH, Tang A, Martinez N, Pickett W, Murga M, Yost SE, Stewart D, Zhang J, Ede N, Modi B, Kessler J, Rand J, Fong Y. Yuan Y, et al. Among authors: tang a. Ther Adv Med Oncol. 2023 Nov 10;15:17588359231210675. doi: 10.1177/17588359231210675. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028143 Free PMC article.
3,570 results